Liraglutide - 4Moving Biotech
Alternative Names: 4P 004Latest Information Update: 28 Sep 2025
At a glance
- Originator INSERM; Sorbonne University
- Developer 4Moving Biotech; 4P-Pharma
- Class Anti-inflammatories; Antihyperglycaemics; Antiparkinsonians; Antirheumatics; Glucagon-like peptides; Obesity therapies
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Osteoarthritis
Most Recent Events
- 28 Sep 2025 No recent reports of development identified for phase-I development in Osteoarthritis in Belgium (Intra-articular, Injection)
- 08 Apr 2025 Phase-II clinical trials in Osteoarthritis (Intra-articular), prior to April 2025
- 08 Apr 2025 4Moving Biotech announces intention to launch liraglutide by 2030